UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12B-25
COMMISSION FILE NO. 001-12671
NOTIFICATION OF LATE FILING
(Check One): |_| Form 10-K |X| Form 10-KSB |_| Form 20-F |_| Form 11-K
|_| Form 10-Q |_| Form N-SAR
For Period Ended: December 31, 2005
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 10-KSB
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
-------------------
================================================================================
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
================================================================================
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
VERIFIED ANY INFORMATION CONTAINED HEREIN.
================================================================================
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
--------------------------------------------------------------------------------
PART 1--REGISTRANT INFORMATION
--------------------------------------------------------------------------------
Full Name of Registrant
Kiwa Bio-Tech Products Group Corporation
--------------------------------------------------------------------------------
Former Name if Applicable
Tintic Gold Mining Company
--------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
415 West Foothill Blvd, Suite 206, Claremont, California 91711-2766
--------------------------------------------------------------------------------
City, State and Zip Code
Claremont, California 91711-2766
PART II--RULES 12B-25(B) AND (C)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort of expense;
(b) The subject annual report, semi-annual report, transition report
on Form 10-K, Form 10-KSB, Form 20-F, 11-K or Form N-SAR, or portion
|X| thereof, will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the prescribed due
date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III--NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 10-KSB, 20-F, 11-K,
10-Q, N-SAR, or the transition report portion thereof, could not be filed within
the prescribed time period.
Kiwa Bio-Tech Products Group Corporation (the "Company") could not
complete the filing of its Annual Report on Form 10-KSB for the year ended
December 31, 2005 due to a delay in obtaining and compiling information required
to be included in the Company's Form 10-KSB, which delay could not be eliminated
by the Company without unreasonable effort and expense. In accordance with Rule
12b-25 of the Securities Exchange Act of 1934, the Company will file its Form
10-KSB no later than the 15th calendar day following the prescribed due date.
PART IV--OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
(Name) (Area Code) (Telephone Number)
(909) 626-2358
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s). |X| Yes |_| No
--------------------------------------------------------------------------------
(3) It is anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report of portion thereof?
|X| Yes |X| No
--------------------------------------------------------------------------------
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
--------------------------------------------------------------------------------
Kiwa Bio-Tech Products Group Corporation
--------------------------------------------------------------------------------
(Name of Registrant as Specified in Charter)
Date March 30, 2006 By /s/ Wei Li
-------------- ---------------------------
Wei Li
Chief Executive Officer
INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
--------------------------------------------------------------------------------
ATTENTION
--------------------------------------------------------------------------------
================================================================================
INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL
VIOLATIONS (SEE 18 U.S.C. 1001).
================================================================================